Expression and prognostic values of ARID family members in breast cancer

Zhang, Jinfeng; Hou, Siyu; You, Zilong; Li, Guozheng; Xu, Shouping; Li, Xianyong; Zhang, Xianyu; Lei, Bo; Pang, Da

doi:10.18632/aging.202489

Cited by 27 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 90%

“…Moreover, ARID1A may have a high prognostic value for drug sensitivity. Xu et al verified a vital function of ARID1A in breast luminal lineage maintenance, which further revealed that the expression of ARID1A in the luminal type was higher than that in the nonluminal type (31,32). The loss of ARID1A was more general in post-endocrine therapy metastatic cancer and regarded as the top candidate whose loss indicated fulvestrant resistance (32,34).…”

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 99%

“…Previous studies support ARID1A deletion as an independent prognostic factor for invasive breast cancer (30)(31)(32). The low mRNA expression of ARID1A is related to shorter overall survival in luminal A and human epidermal growth factor receptor 2 (HER2)-rich breast cancer (31). Takao et al analyzed the immunohistochemical staining to evaluate the relationship between the downregulation of ARID1A and poor disease-free survival (33).…”

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 99%

See 2 more Smart Citations

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

Distant metastasis is the principal cause of mortality for breast cancer patients. Targeting specific mutations that have been acquired during the evolution process of advanced breast cancer is a potential means of enhancing the clinical efficacy of treatment strategies. In metastatic breast cancer, ARID1A is the most prevalent mutation of the SWI/SNF complex, which regulates DNA repair, recombination, and gene transcription. The low expression of ARID1A is associated with poor disease-free survival and overall survival of patients with luminal A or HER2-rich breast cancer. In addition, ARID1A plays a prominent role in maintaining luminal characteristics and has an advantage for identifying responses to treatment, including endocrine therapies, HDAC inhibitors and CDK4/6 inhibitors. The therapeutic vulnerabilities initiated by ARID1A alterations encourage us to explore new approaches to cope with ARID1A mutant-related drug resistance or metastasis. In this review, we describe the mutation profiles of ARID1A in metastatic breast cancer and the structure and function of ARID1A and the SWI/SNF complex as well as discuss the potential mechanisms of ARID1A-mediated endocrine resistance and therapeutic potential.

show abstract

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 90%

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 99%

Section: Arid1a Mutation and Prognostic Values In Breast Cancermentioning

confidence: 99%

See 1 more Smart Citation

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A database mining study recently assessed the expression of Arid family members including Arid5a based on The Cancer Genome Atlas (TCGA) data and also evaluated the prognostic value of each member in breast cancer patients ( 94 ). The mRNA expression of Arid3a, Arid3b, Arid4b, Jarid1b, Jarid1c , and Jarid2 was higher, whereas Arid1b, Arid3c, Arid4a, Arid5a, Arid5b , and Jarid1a mRNA expression was lower in tumor tissues compared with controls.…”

Section: Association Of Arid5a In Cancermentioning

confidence: 99%

“…A Kaplan-Meier analysis revealed that lower expression of Arid5a mRNA was associated with poor overall survival in the luminal type and all breast cancer patients. Based on an analysis of online datasets, Arid5a is considered a good candidate for tumor treatment in breast cancer ( 94 ); however, it will be necessity to conduct further studies to provide more experimental evidence.…”

Section: Association Of Arid5a In Cancermentioning

confidence: 99%

Recent Advances in the Role of Arid5a in Immune Diseases and Cancer

Nyati

Kishimoto

2022

Front. Immunol.

View full text Add to dashboard Cite

AT-rich interactive domain 5a (Arid5a) is a nucleic acid binding protein. In this review, we highlight recent advances in the association of Arid5a with inflammation and human diseases. Arid5a is known as a protein that performs dual functions. In in vitro and in vivo studies, it was found that an inflammation-dependent increase in Arid5a expression mediates both transcriptional and post-transcriptional regulatory effects that are implicated in immune regulation and cellular homeostasis. A series of publications demonstrated that inhibiting Arid5a augmented several processes, such as preventing septic shock, experimental autoimmune encephalomyelitis, acute lung injury, invasion and metastasis, immune evasion, epithelial-to-mesenchymal transition, and the M1-like tumor-associated macrophage (TAM) to M2-like TAM transition. In addition, Arid5a controls adipogenesis and obesity in mice to maintain metabolic homeostasis. Taken together, recent progress indicates that Arid5a exhibits multifaceted, both beneficial and detrimental, roles in health and disease and suggest the relevance of Arid5a as a potential therapeutic target.

show abstract